Lung cancer and immunotherapy: a real-life experience from second line and beyond

Lung cancer and immunotherapy: a real-life experience from second line and beyond

This study assessed the efficacy of anti-PD-1/PD-L1 agents in real life when used in second line or beyond. Patients with advanced non-small-cell lung cancer progressing after standard chemotherapy and receiving immunotherapy in the second line or beyond were included. One hundred and ten patients w...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Future oncology (London, England) England), 2019-09, Vol.15 (26), p.3025-3032
Hauptverfasser: El Karak, Fady, Gh Haddad, Fady, Eid, Roland, Al Ghor, Maya, El Rassy, Elie, Ahmadieh, Nizar, Choullamy, Theresia, Halim, Nour A, Tfayli, Arafat, Farhat, Fadi, Kattan, Joseph, Nasr, Fady, Ghosn, Marwan, Assi, Hazem I
Format: Artikel
Sprache:eng
Schlagworte:
Aged
Antineoplastic Agents, Immunological - administration & dosage
Antineoplastic Agents, Immunological - adverse effects
Antineoplastic Agents, Immunological - therapeutic use
B7-H1 Antigen - antagonists & inhibitors
Biomarkers, Tumor
Cancer therapies
checkpoint inhibitors
Chemotherapy
Clinical trials
Disease control
experience
Female
Hormone replacement therapy
Humans
Immunotherapy
Immunotherapy - adverse effects
Immunotherapy - methods
Lung cancer
Lung Neoplasms - drug therapy
Lung Neoplasms - immunology
Lung Neoplasms - mortality
Lung Neoplasms - pathology
Male
Metastasis
Middle Aged
non-small-cell lung cancer
Patients
Population
Prognosis
real life
real-world
Retreatment
second line
T-Lymphocyte Subsets - drug effects
T-Lymphocyte Subsets - immunology
T-Lymphocyte Subsets - metabolism
Treatment Outcome
Tumors
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:This study assessed the efficacy of anti-PD-1/PD-L1 agents in real life when used in second line or beyond. Patients with advanced non-small-cell lung cancer progressing after standard chemotherapy and receiving immunotherapy in the second line or beyond were included. One hundred and ten patients were included with PD-L1 expression above 50%, between 1–49 and
ISSN:1479-6694
1744-8301
DOI:10.2217/fon-2019-0144